Chris has over 15 years of senior management experience as President, CBO and CFO of various private and public life sciences, medical technology, and technology companies.  Additionally, he has served as a member of the Board of Directors of both public and private companies, and has chaired their respective Audit Committees and Compensation Committees. 

During his career as a C-level executive, Chris has successfully raised over $500M in private and public financings, completed over $1.0B in M&A transactions, negotiated over $300M in debt instruments for companies.   From 2007 – 2013 he served as the Chief financial Officer at  Anthera Pharmaceuticals, a pharmaceutical development company, and from 2010 – 2013 also served as Chief Business Officer at Anthera Pharmaceuticals.  Most recently beginning in 2014, Chris was interim CEO and subsequently CFO for Hansen Medical (HNSN) until the sale of the company to Auris Robotics in July 2016.  Chris has also served as a partner in FLG Partners since January 2014.

Chris earned his B.S. from California Polytechnic State University – San Luis Obispo, and a MBA from St Mary’s University.  Chris currently sits on the Board of Directors of Epibiome.

Dr. Ronald L. Shazer, M.D., M.B.A. joined Inspyr Therapeutics in August 2016 as Senior Vice President and Chief Medical Officer. Previously Dr. Shazer served as TRACON Pharmaceuticals Inc., Chief Medical Officer since October 2015. Dr. Shazer served as Senior Director, Clinical Lead Oncology at Pfizer where he led the clinical development of multiple oncology compounds including antibody drug conjugates, dual targeting T-cell engaging antibodies, and immuno-oncology small molecules. Prior to Pfizer, he served as a Director, Global Clinical Research Oncology at Bristol-Myers Squibb from 2011 to 2013 and served as the study lead on the registrational study for elotuzumab (Empliciti™), that subsequently received FDA approval. Prior to Bristol-Myers Squibb, he served as the Head of Clinical Development at Arena Pharmaceuticals during the filing of the NDA for lorcaserin (Belviq®). Dr. Shazer held academic positions in the Department of Medicine at the University of California, San Diego, University of California, Los Angeles School of Medicine, and Cedars-Sinai Medical Center. He completed his residency in internal medicine at Cedars-Sinai Medical Center in 2004. Dr. Shazer earned his B.A. in Economics from the University of California, San Diego, M.D. from the New York Medical College and M.B.A from the Anderson School of Management, University of California, Los Angeles.

Michael Elliott has two decades of experience in clinical trial management, spanning Phase 1 through pivotal Phase 3 trials, both in the United States and internationally in over 20 countries. Over the course of his career, Mr. Elliott has managed 59 company-sponsored clinical trials and 9 investigator-sponsored trials. Before joining Inspyr, Michael was Senior Director, Clinical Operations at NGM Biopharmaceuticals. In this role, he led the clinical operations group for this company, which has multiple programs studying first-in-class, first-in-human product candidates. Previously, he was Director, Clinical Development at Afferent Pharmaceuticals, a company which was acquired by Merck. Prior to Afferent, he was Director, Clinical Operations at Anthera Pharmaceuticals where he led multiple clinical studies and supported the regulatory submission for a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA). Earlier in his career, Michael managed clinical research at Stanford University and the University of California San Francisco. Michael earned a Bachelor of Arts from the University of Pittsburgh and a Master of Arts from Xavier University.

Matthew Boxer, Ph.D. is Inspyr’s Vice President and Co-head of Translational Medicine.  Dr. Boxer joined Inspyr following a nine-year career at the NIH, most recently at NCATS, where he was Medicinal Chemistry Group Leader. At NCATS, he led interdisciplinary teams responsible for small molecule hit to lead and lead optimization for over 25 projects across a wide range of diseases. His experience involved prosecuting targets in oncology, rare genetic disorders, infection and lipid disorders. Recently, Matthew was project lead on a multi-institutional drug discovery project targeting an enzyme frequently mutated in cancer, and delivered a compound ready for investigational new drug (IND)-enabling studies. Also during his tenure, Matthew collaborated with over 30 external investigators from academia, NIH, and the biotechnology sector. His collaborations have spanned across the United States and abroad.  Matthew is an inventor for over 10 patents, with multiple patents licensed by biotechnology companies. He frequently reviews for journals, grants, government and foundations with a focus on drug discovery. Matthew earned a Bachelor of Science in Chemistry from the University of Vermont and a Ph.D. in Chemistry from the University of Chicago. He was a Postdoctoral Fellow at the NIH.

David Maloney, Ph.D. is Inspyr’s Vice President and Co-head of Translational Medicine.  Dr. Maloney joined Inspyr following a nine-year career at the NIH’s National Center for Advancing Translational Sciences (NCATS), where he was a Group Leader in Chemistry and co-led an interdisciplinary project team. NCATS was established to transform the translational science process so that new treatments and cures for disease can be delivered to patients faster. During his tenure at NCATS, David led a team of senior scientists in lead-identification and late-stage lead optimization efforts. He managed a project portfolio encompassing a broad range of therapeutic areas and target classes which involved close collaboration and interaction with leading researchers from around the world in both academia and the private sector. Most recently, he co-led a multi-center, NCI-funded drug discovery effort targeting an enzyme involved in cancer metabolism.  David has co-authored over 75 scientific publications and is co-inventor on over 10 composition of matter patents. In addition, David has served as an ad hoc reviewer for the Defense Threat Reduction Agency (DTRA) and National Institute of Allergy and Infectious Diseases (NIAID) and frequently is invited to review scientific manuscripts. David earned a Bachelor of Science in Chemistry from the University of Vermont and a Doctor of Philosophy in Organic Chemistry from the University of Virginia. Following completion of his PhD, he was a Postdoctoral Fellow at Memorial Sloan-Kettering Cancer Center.